At SaNOtize, our mission is to save lives and improve the quality of life for billions of people across the globe. Our rigorously tested and scientifically validated nitric-oxide-releasing platform enables this natural molecule to be accessible as a nonantibiotic antimicrobial for the first time.
For many topical infections and upper respiratory diseases, the standards of care lack efficacy or have significant side effects. Our nitric oxide-based based products and pipeline have the potential to be transformative for global health, whether treatingcommon skin infections or helping manage the next viral pandemic.
SaNOtize has variety of strategic options on the horizon, from licensing or selling the rights to its technology for a specific indication to maintaining all rights and commercializing a suite of products.
We invite investors and potential partners to reach out to our business development team. Together, we can make a lasting difference in infection care around the world.
Nitric oxide (NO) is a nano-molecule naturally produced in the body. Since 1999, the medical community has used gaseous NO, delivered via large gas cylinders in conjunction with a ventilator, to treat respiratory failure in premature babies. While numerous clinical studies had also shown NO to be a potent antimicrobial against viruses, bacteria, and fungi, delivering gaseous NO through cylinders is impractical for treating many infectious diseases, especially topical ones.
SaNOtize’s key innovation is the development of a proprietary liquid formulation that releases NO gas in therapeutic concentrations. This patented platform – known as Nitric Oxide Releasing Solution or NORSTM – is a practical delivery system that can be adapted across applications while controlling the dose of NO released. It allows NO to be used as an antimicrobial for the first time. .
The company’s lead therapy, Nitric Oxide Nasal Spray (NONSTM), is currently available to a quarter of the world’s population. A landmark regulatory approval occurred in 2022, when NONS was approved in India for early treatment of COVID-19 in high-risk individuals – this marked the first-ever regulatory drug approval of NO to treat an infection. SaNOtize believes this event may pave the way for additional approvals of NO for the treatment of other types of microbial infection. .
In the span of a few short years, SaNOtize developed a new end-to-end anti-infective treatment and prevention paradigm, secured the necessary funding, and built the manufacturing and logistics to support its roll-out. SaNOtize’s formulation, novel delivery device, and the fill-finish manufacturing machines that produce the product were fully designed and developed by the company.
SaNOtize maintains an assertive patent development strategy, focused on expanding the portfolio and therapeutic opportunities. The portfolio includes multiple foundational NORSTM patents, and has weathered the rigor of FTO/defensibility as well as independent investors and partner due diligence. It includes prosecution of patents specifically expanding on the formulation, delivery methods, and methods for dose verification. SaNOtize possesses many years of know-how, developed by using our formulations and verifying effective doses.
NORSTM is being studied across several applications to treat skin, nail, and respiratory infections. In addition to SaNOtize’s lead product (NONSTM), the company’s full pipeline has the potential to have a significant impact on global health and equitable access to infection care. Importantly, as a non-antibiotic antimicrobial, NORSTM may reduce the use of antibiotics and allow them to be reserved for more severe infections. Reducing overuse of antibiotics can help slow the development of antimicrobial resistance, which is a significant global concern. Additionally, NORSTM can help serve populations around the world who lack adequate access to care for common topical bacterial, viral, and fungal infections.